KR100786121B1 - Composition for the use of preventing adhesion of infectious disease pathogen to human cell - Google Patents

Abstract

A composition comprising pectin is provided to be used as an agent for preventing and treating gastric diseases, periodontal diseases and skin diseases such as acne vulgaris, and atopy by securing high activity of inhibiting human cell hemagglutination caused by Porphyromonas gingivalis, Propionibacterium acnes and Staphylococcus aureus. A composition for preventing and treating periodontal diseases, acne vulgaris, atopy or gastric diseases through inhibition of adhesion of infectious disease pathogen to human cell comprises pectin as an effective ingredient, wherein the pectin shows the effective inhibitory activity in a concentration range of 0.0001-0.1 mg/ml.

Description

Composition for the use of preventing adhesion of infectious disease pathogen to human cell}

1 shows the properties of pectin and alginic acid. (a) The structure of citrus pectin sold commercially. (b) Purification profile of citrus pectin using Sephacryl S200 gel filtration chromatography. (c) The structure of alginic acid (linear structure consisting of a polymer of β-1,4 linked D mannuronic acid (M) and α-1,4) linked L guluronic acid (G)).

Figure 2 shows the results of measuring the activity of pectin against various bacteria. (a) shows the result of erythrocyte agglutination (+: aggregation occurs,-: aggregation does not occur, and there is inhibitory activity). (b) is a 100-fold magnification of microscopic observation showing the effect of inhibiting hemagglutination in the concentration of 0.0001 mg / ml for Popiromonas jinjibali. PC (Positive control) is a reaction of erythropoietin with only Pyrophyllosis jinjivalis without adding pectin. (c) activity of inhibiting NIH 3T3 cell adhesion of Staphylococcus aureus according to the concentration (0.0001 ~ 0.1 mg / ml).

Figure 3 shows the antiadhesive activity of various bacteria of pectin. Cocos skin flora Staphylococcus epidermidis (Staphylococcus epidermis , Escherichia coli ), anti-adhesion reaction by Lactobacillus acidophilus .

Figure 4 shows the antiadhesive activity of alginic acid on erythrocyte aggregation by Helicobacter pylori. PC (Positive control) reacts only Helicobacter pylori to red blood cells without adding alginic acid.

The present invention relates to a composition for inhibiting human cell binding of an infectious disease pathogen containing pectin or alginic acid as an active ingredient, and more specifically, a pectin that inhibits mucosal epithelial cell binding in humans of oral periodontal causative bacteria, skin acne bacteria and atopic bacteria. In addition, the present invention relates to a composition for inhibiting human cell binding of an infectious disease pathogen containing alginic acid, which also inhibits epithelial cell binding of gastrointestinal causative bacteria.

Periodontitis is a widespread gum disease in which tissues and alveolar bones attached around the teeth are destroyed by bacterial bacteria. Periodontitis is known as an adult disease that increases with age, but especially from the age of 40 to old age, periodontitis is almost a chronic symptom, which is a very important factor for old age health. It is affecting.

Although it is not possible to represent only one bacterium that causes periodontitis, Porphyromonas gingivalis ; Popiromonas) is a Gram-negative bacterium and is known as the most important pathogen causing chronic severe periodontitis in the human body. The genome sequence of this pathogen has recently been identified and is the case of the first genome sequence of a pathogenic microorganism causing disease in the oral cavity (1). Because porphyromonas causes disease by cell adhesion that binds to epithelial cells in the oral mucosa, identification of adhesin proteins involved in cell adhesion will be made soon due to genome sequencing performance. It is expected.

Acne (acne vulgaris, pimples) is one of the most common skin diseases from adolescence to middle age. Acne is an inflammatory lesion of the hair follicle in the skin and the sebaceous gland, the oil glands of the skin (2), and it occurs in many sebaceous glands of more than 3 million on the skin, and mainly occurs on the face, back, and the breast (3). The sebaceous glands send large amounts of sebum out through the hair follicles, and acne develops when the sebum secretion is too high or the hair follicles are blocked. Sebaceous glands are the target organs of sex hormones, especially the androgen, a male hormone, and when sexual hormones are active as a secondary sex during puberty, sebaceous glands mature and multiply, and sebum secretion increases. Thus, about 8-9 out of 10 men and women who enter puberty are known to have acne, and in the United States, about 80% of the puberty population is affected (4).

Internal causes of acne include sebaceous glands secreted by endocrine effects such as hormonal changes depending on mental and physical stress, abnormalities of their components, and blockage of sebaceous glands or hair follicles due to excessive sebum secretion. There is also a strong relationship between cortisol caused by stress and a hormone called progesterone during women's menstrual periods (5). External causes of acne bacilli (Propionibacterium living in the sebaceous glands to increase sebum Because of the stimulating factor of acnes ), the epithelial wall of the epithelium is thickened, the keratin of the inner surface of the epithelium is thickened, obstruction due to abnormal keratinization of the hair follicles and oxygen inflow into the hair follicles is reduced. This phenomenon is a very good development condition in anaerobic P. acnes , the causative agent of acne, and promotes the growth in acne lesions (6). In general, healthy skin contains bacteria such as acne bacilli and staphylococci. Depending on the human person, there are several hundred to hundreds of thousands of acne bacillus in 1 cm ² of skin.

P. acnes are Gram-positive bacteria that are rod-shaped anaerobic acne bacilli (7). It is morphologically very similar to Corynebacterium and is generally non-toxigenic. Anaerobic, but limited, aerobic (microaerobic) proliferation is possible, it is a representative skin flora of the skin and hair follicles causing acne. The genome sequence of P. acnes was identified in 2004, and this is the first time that a complete genome sequence of a skin-derived microorganism has been identified (8, 9). It is expected to be of great help to study the characteristics of symbiotic mechanisms as the most common bacteria on human skin. The number of bacteria and sebum secretion in P. acnes is correlated, and the sebum-rich area, the seborrheic area, is the acne-prone area, and this area is also the site of high P. acnes count (7).

Atopic dermatitis is one of the most common skin diseases and is a chronic inflammatory skin disease (10). Atopic dermatitis usually occurs in newborns around 3 months of age, with a prevalence rate in 10% of children and more than 30% of school-aged children.Atopic dermatitis, like other allergic diseases, shows a high increase ( 11-13).

External factors of atopy include chemicals such as fragrances, preservatives, disinfectants, and solvents, as well as indoor dust and mite, mold, food, pollen, and dogs. Inhaled antigens penetrate the damaged skin barrier of atopic dermatitis and cause contact dermatitis. 90% of patients with atopy accumulate Staphylococcus aureus on the skin, and many studies show that epithelial cells of atopic patients are infected with staphylococcus. However, the mechanism of infection and propagation of Staphylococcus aureus in epithelial cells is not clear for these atopic patients.

S. aureus is not only a primary cause of atopic dermatitis, but also a secondary cause of infections such as skin pores, clogged glands, or invasion (11). Within 10% of normal people, Staphylococcus aureus is found in the skin in 90% of atopic patients. Enterotoxin, a staphylococcus aureus, aggravates atopic dermatitis very much. It is also involved in the development of toxic shock syndrome due to superantigens in blood vessels (14). More importantly, MRSA (methicillin-resistant Staphylococcus) , a variant of S. aureus The problem is caused by the increase of antibiotic resistant bacteria such as aureus ). Therefore, treatment of atopic dermatitis should be carried out not only to treat allergies but also to remove staphylococcus aureus, and it is an urgent need for antibiotics that can be combined with antibiotics.

In general, the skin flora, which plays a role of mixing sweat and sebum, is beneficial to the skin as a beneficial flora, while too much harmful flora, such as acne bacilli and staphylococci, causes the balance of the skin to collapse. Staphylococcus as a skin flora epidermidis is a nonpathogenic, gram-positive, coagulase-negative bacterium that coexists on human skin in healthy people. However, unlike skin, infection of a patient's surgical site after general surgery or internal surgery may act as a pathogen (15, 16). Lactobacillus acidophilus is important for the maintenance of the intestinal microflora (17). By being in the gut, they play a beneficial role in promoting animal growth and protecting them from pathogens (18). Escherichia coli is an anaerobic bacterium that lives in the gastrointestinal tract of mammals, while strains such as E. coli O157 cause human disease (19), but most other strains help digest food in the digestive tract, and vitamins B and K Create Therefore, these bacteria present in the human body can be divided into beneficial bacteria and useless bacteria, even if the beneficial bacteria can be seen that can be transformed into pathogens causing disease depending on the environment or body parts.

Helicobacter pylori ) is a Gram-negative bacterium known to cause chronic, acute gastritis, gastric ulcer and gastric cancer in the human body. In the industrial world, more than half of the population over 60 years of age is infected, and in developing countries, most of the population has been infected since childhood. Infants between the ages of two and eight years are infected with about 10% annually, so most of the teenagers are infected. In recent years, it has been established that inflammation occurs when infected by Helicobacter. When inflammation spreads to the submucosal layer of the stomach, it develops gastric ulcers and does not immediately progress to gastric cancer, but when helicobacter is infected, it is known that 3-5 times more likely to progress to gastric cancer.

Helicobacter binds to mucosal epithelial cells in the gastrointestinal tract, and it has been reported that the binding mechanism mainly depends on the interaction between carbohydrates and bacterial surface proteins that recognize it. Particularly recognized carbohydrates have been reported such as sulfated carbohydrates of mucin glycoproteins, sialyllactose and fucosylated Lewis b antigens. Recently, efforts have been made to inhibit bacterial cell binding using glycosphingolipids or mucin proteins in saliva.

Antibiotics are mainly used to treat and protect infectious disease pathogens, especially acne and atopy, but many antibiotics are resistant to antibiotics due to antibiotic misuse and abuse.

Carbohydrates have various functions in vivo, and carbohydrates such as glycoproteins or glycolipids on the surface of cells have the function of ligands that recognize proteins. Provide a place for attachment. When the pathogen penetrates the human cells to proliferate, it causes inflammation and causes a disease, and when the pathogen is initially blocked from the attachment of the human cell to the pathogen, it plays a role of disease prevention. If developed as an anti-adhesive drug using human cell surface carbohydrates, which play an important role in the initial process of human pathogen infection, it can block the initial infection of pathogens. Therefore, anti-adhesion treatment and prevention are developed as bioenvironmental therapies that maintain the skin's microbial balance by selectively reducing contact between human tissue and pathogens by eliminating or preventing the attachment of infectious agents and selectively allowing the attachment of beneficial bacteria. It is possible.

Thus, the study of the interaction and binding between carbohydrates of human cells and the bacterial surface proteins that recognize them will contribute to understanding the mechanism of adhesion of these cells to human skin cells. Bacterial cells generally respond to hemagglutination, a reaction that occurs when protein-adhesive receptors (adhesin) on the surface of bacteria recognize carbohydrates or proteins on the surface of human cells such as red blood cells. Hemagglutination, which has been used for cell-to-cell recognition, has been widely applied to cell-to-cell recognition because of the property that the surface of red blood cells has the same or similar carbohydrate composition as human epithelial cells. It is possible to study the mutual recognition between bacterial surface proteins and human cells through erythroid aggregation. The important point is that the carbohydrates of the skin cells and carbohydrates of the red blood cells are the same or similar, so that inhibiting the binding by interaction can be used for the treatment and prevention of diseases caused by pathogens.

Pathogens bind to erythrocytes to induce agglutination, and the present inventors have already found that acidic polysaccharid fractions separated from ion-exchange resins and gel filtration resins in water-soluble extracts of Korean ginseng inhibit the hemagglutination by pathogens. And the inhibitory effect was relatively higher than other polysaccharide fractions (20). In particular, as carbohydrate engineering techniques are developed, chemical degradation and sequence structure experiments are possible with low-molecular-weight oligosaccharides of heparin polysaccharides. .

Therefore, it is important to develop a sugar copolymer using carbohydrates recognized by bacterial surface protein receptors (adhesin). When antibiotics or chemicals developed for the treatment of skin diseases are very limited, the emergence of resistant bacteria due to antibiotic abuse and the harmonious balance of beneficial / unproductive bacteria in the human body are destroyed. to be. The use of existing antibiotics or chemicals not only adversely affects the development but also cell destruction, while new substances that inhibit carbohydrate recognition and interaction on the surface of human cells inhibit the intercellular binding and block the symbiosis of skin disease cells. It is also important in that it is a non-destructive technique for minimizing skin diseases such as acne. Therefore, the development of carbohydrates that inhibit the recognition or adhesion of human cells will create new bio-environmental materials in the 21st century.

A representative example of this non-destructive technology is breast milk or saliva. In other words, because breast milk or saliva contains physiological glycopolymers, it essentially plays a role of clearing the digestive tract by suppressing the attachment of ineffective or pathogenic bacteria in the human body. The present invention is a technology to search for materials that inhibit the stomach, oral cavity, skin cell adhesion, proliferation and activity, but does not selectively inhibit the flora and beneficial bacteria, in particular technology using carbohydrate engineering research method newly recognized in the biotechnology field to be.

Therefore, the present inventors have made intensive studies to overcome the problems of the prior art, in the case of compositions containing pectin or alginic acid as an active ingredient, these active ingredients inhibit the infection pathogen-human cell adhesion within a certain concentration range It was confirmed that the activity was shown to complete the present invention.

Accordingly, the main object of the present invention is to provide a composition containing pectin or alginic acid having a specific effect of significantly inhibiting human cell binding of an infectious disease pathogen and having no specific inhibitory effect on other beneficial bacteria in humans. .

Another object of the present invention to provide a composition for preventing and treating periodontal disease, acne, atopy and gastric disease containing the pectin or alginic acid of the present invention as an active ingredient.

According to an aspect of the present invention, the present invention provides a composition for inhibiting human cell binding of an infectious disease pathogen containing pectin or alginic acid as an active ingredient.

In the human cell binding inhibitory composition of the present invention, preferably, the infectious disease pathogen is oral periodontitis causative bacteria, skin disease acne bacilli, atopic skin pathogens or gastric disease pathogens.

In the human cell binding inhibitory composition of the present invention, preferably the pectin shows an effective inhibitory activity in the range of 0.0001 ~ 0.1 mg / ml, the alginic acid exhibits an effective inhibitory activity in the concentration range of 0.25 ~ 0.5 mg / ml It features. The present invention was based on the possibility of inhibiting pathogen cell adhesion of pectin and alginic acid. Pectin showed effective inhibitory activity at low concentrations from 0.0001 to 0.1 mg / ml, as measured by H. pylori , P. gingivalis , P. acnes and S. aureus . Alginic acid was observed inhibitory activity in the concentration range of 0.25 ~ 0.5 mg / ml higher than this.

In the human cell binding inhibitory composition of the present invention, preferably, the composition is characterized by showing a strong specific inhibitory effect only on the hemagglutination reaction by the pathogen. In the present invention, by performing experiments on the E. coli strains parasitic in the human body, it was demonstrated that the strong specific inhibitory effect only in the hemagglutination reaction by the pathogen.

According to another aspect of the present invention, the present invention provides a composition for preventing and treating periodontal disease, acne, atopic and gastric diseases, containing pectin or alginic acid as an active ingredient. The invention is Helicobacter pylori , Porphyromonas gingivalis , Staphylococcus aureus , Propionibacterium It is composed of specific sugars that inhibit erythroid aggregation caused by acnes . The pectin or alginic acid of the present invention includes sugars in the form of salts or complexes of pectin or alginic acid and derivatives thereof having various molecular weights as long as they have the cell adhesion inhibitory activity of the pathogen. These factors are considered to be important factors that inhibit the recognition of human gastric mucosa, oral mucosa and skin epithelial cells of H. pylori , P. gingivalis , P. acnes and S. aureus .

The pectin of the present invention can be obtained commercially or obtained by combining a known method used for separating and extracting peels, sugar cane, apple dregs of fruits and the like, alone or suitably, alginic acid is commercially purchased or extracted from seaweeds Can be obtained.

Pectin is a polysaccharide compound of various molecular weights and is classified according to the degree of esterification. It is found in fruit peels such as citrus fruits, apples, oranges, and lemons, as well as in apples and sugar cane. As a constituent of the cell wall or intermediate layer, it is a substance that is present between cellulose and hemicellulose between cell membranes and cells and binds cells to cells. Thus, pectin is present in almost every part of the plant. Fruits are more present in the skin and around the skin than in the flesh. Pectin is easy to hydrate, has a strong hygroscopicity, forms a hydrophilic colloidal solution in water and has a very high viscosity. Pectin is a water-soluble dietary fiber with excellent swelling properties, which is difficult to be broken down by digestive enzymes in the human body.

When seaweed such as seaweed or kelp is added to water, it becomes muggy. Alginic acid is extracted from brown algae using sodium carbonate. Alginic acid is insoluble in water, but when combined with potassium, sodium, and calcium, it dissolves well in water to form a mucus. Using these properties, alginic acid is used in food processing as a food additive such as stabilizer, thickener, emulsifier and also for medicine. In fact, it is used as a stabilizer for ice cream, orange juice, beer and cheese. Alginic acid is not digested or absorbed, so jelly made with alginic acid is sometimes used as a diet food.

The pectin or alginic acid of the present invention may be prepared by a method known in the pharmaceutical field for use as the composition for preventing and treating such powder, and may be mixed with itself or a pharmaceutically acceptable carrier, excipient, diluent, etc. And may be prepared in the form of granules, tablets, capsules, or injections. In addition, they may be administered orally or parenterally.

The dosage of pectin or alginic acid according to the present invention as an active ingredient may be appropriately selected according to the age, sex, weight, condition, and symptoms of the disease of the patient. Preferably, the daily pectin of the adult is 0.01 to 100 mg. , Alginic acid may be administered from 50 to 500 mg.

Hereinafter, the present invention will be described in more detail.

In the present invention, attention was paid to the very important biophysical chemical properties of the specific sugars pectin and alginic acid. In particular , the minimum effective amount of pectin, which inhibits hemagglutination by P. gingivalis , P. acnes and S. aureus , is 0.0001 to 0.1 mg / ml at low concentrations. Figure 2 shows the results of measuring the activity of pectin against various bacteria. (a) is a result table of erythrocyte aggregation reaction (++++: aggregation reaction occurs strongly,-: aggregation reaction does not occur, and there is inhibitory activity). (b) is a microscopic photograph showing the effect of inhibiting hemagglutination in the concentration of 0.0001 mg / ml for Pyromonas jinjivalis (100-fold magnification) (Positive control (PC) without adding pectin) Erythrocyte agglutination reaction by erythropoiesis). (c) is an activity result that inhibits NIH 3T3 cell adhesion of Staphylococcus aureus according to the concentration (0.0001 ~ 0.1 mg / ml). Alginic acid has a lower concentration (0.25 to 0.5 mg / ml), but is characterized by its antiadhesive activity against H. pylori . Figure 4 shows the anti-adhesive activity of alginic acid to erythrocyte agglutination by Helicobacter pylori (PC (Positive control) is a reaction of erythrocytes by only Helicobacter pylori reaction to erythrocytes without addition of alginic acid). Alginic acid has an inhibitory effect on hemagglutination by Helicobacter pylori at a concentration of 0.25 mg / mL.

Glucuronic acid (galcururonic acid), galacturonic acid (rhamnose), arabinose, xylose, glucose (glucose), galactose (galactose), pectin used in the present invention (citrus peel) was purchased from Sigma, USA. Erythrocytes were obtained from Korea University School of Medicine, and used after treatment with anticoagulant and trypsin enzyme. Pyromonas bacteria (ATCC33277) are 50% ground beef, 3% trypticase, 0.5% yeast extract, 0.05% cysteine, 10 ml / L hemin, 0.15 ml / L vitamin K1 The medium was incubated at 37 ° C., 10% carbon dioxide, and 10% hydrogen for 3 days, and stored in liquid nitrogen. P. acnes (ATCC 11828) was incubated for 2 days under anaerobic conditions in brain-heart infusion medium. S. aureus and S. epidermidis bacteria were obtained from Korea University Medical Center hospital and liquid in aerobic condition in brain-heart infusion medium. Incubated. All the cells were centrifuged at 6,000 g for 30 minutes and stored in 170 ℃ liquid nitrogen was used for the experiment. Helicobacter (ATCC33277) was prepared at 37 ° C. and 10% CO ₂ in brucella broth containing 10% (v / v) fetal bovine serum and 0.2% (v / v) 2,6-di-methyl-cyclodextrin (CD). After culturing in air for about 2 days, harvested and stored in liquid nitrogen was used for the experiment.

E. coli (BL21 (DE3), BL21 (DE3) / pLysS) used in the present invention was incubated for 6 hours at 37 ° C. without antibiotic treatment in Luria-Bertani (LB) agar medium, and the cultured E. coli was centrifuged at −70 ° C. The L. acidophilus was used in the experiment after storing the liquid culture solution from the Korea Microorganism Conservation Center. Figure 3 shows the antiadhesive activity of various bacteria of pectin. Skin fungus Staphylococcus epidermidis (Staphylococcus epidermidis), Escherichia coli (Esherichia coli), Lactobacillus asidophilus (Lactobacillus acidophilusAnti-adhesion reaction by

Purified pectin and alginic acid used in the present invention was purified by Sephacryl S200 gel filtration chromatography after purchasing pectin obtained from citrus peel was used purified pectin size of about 80 ~ 100 kDa (Fig. 1). The molecular weight of the purified pectin was compared using a Dextran (dextran) standard sample. Alginic acid was used as it was (about 800 ~ 1200 kDa). 1 shows the properties of pectin and alginic acid. (a) is the structure of commercially available citrus pectin. (b) is the purification profile of citrus pectin using Sephacryl S200 gel filtration chromatography. (c) is the structure of alginic acid (linear structure consisting of a polymer of β-1,4 linked D mannuronic acid (M) and α-1,4 linked L guluronic acid (G)).

Hereinafter, the present invention will be described in more detail with reference to Examples. Since these examples are only for illustrating the present invention, the scope of the present invention is not to be construed as being limited by these examples.

Example  One. P. gingivalis Inhibition of hemagglutination by

The cultured P. gingivalis was diluted with phosphate buffer solution, mixed with the same amount of red blood cell solution and reacted with light stirring at room temperature for 30 minutes to 3 hours, or overnight at 4 ° C. It was. For the inhibitory activity on the aggregation reaction using pectin, the mixture of the Pyrromonas solution and the pectin solution was reacted at room temperature or 4 ℃, and then reacted by mixing the erythrocyte solution, and the degree of aggregation reaction was measured using a microscope. It was.

As a result of measuring activity inhibiting erythrocyte aggregation by porphyromonas, pectin showed high inhibitory activity at a low concentration of 0.0001 mg / ml (FIGS. 2A and B).

Example  2. Caused by acne bacilli and Staphylococcus aureus Antiadhesion  activation

The cultured P. acnes and S. aureus were diluted with phosphate buffer solution, mixed with the same amount of red blood cell solution and reacted with light stirring at room temperature for 30 minutes to 3 hours, or overnight. It was. In order to inhibit the coagulation reaction using pectin, P. acnes , S. aureus solution and pectin solution were mixed and reacted at room temperature, and then reacted by mixing red blood cell solution. It was measured by.

Pectin showed inhibitory activity at low concentrations of 0.01 mg / ml, respectively, as a result of inhibition of hemagglutination by P. acnes and S. aureus . In general, specific monosaccharides, such as glucuronic acid, show cell adhesion inhibitory activity at concentrations of about 0.5 mg / ml or more, ie high molarity (data not shown). On the contrary, it can be seen that pectin, which is the subject of the present invention, has a relatively high activity (FIG. 2A).

Example  3. Cause of skin disease NIH3T3  Cell adhesion and inhibition of pectin adhesion

NIH3T3 cells were pre-cultured in 96 well cell culture dishes, and then a mixture of cultured S. aureus and pectin was added to NIH3T3 cells. After 30 minutes of adhesion reaction, skin bacteria that did not adhere to NIH3T3 were removed by washing, and only the skin bacteria attached to the cells were collected again, diluted to an appropriate concentration, incubated in solid medium, and the number of colonies grown in solid medium was counted. It was. Inhibition of S. aureus adhesion to the NIH3T3 cells of pectin was measured by comparing the degree of adhesion of the pectin-treated group to the group containing only the skin bacteria without the pectin. It showed an inhibitory activity of 30%, and showed an inhibitory activity corresponding to the hemagglutination reaction (FIG. 2C).

Example  4. S. epidermidis Escherichia coli, Lactobacillus  Inhibition of hemagglutination by bacteria

Cultured dermal bacteria S. epidermidis , Escherichia coli, and Lactobacillus were diluted with a buffer solution, mixed with an equal amount of red blood cell solution, and then reacted with a slight stirring at room temperature for 30 minutes to 3 hours, or overnight. Reaction. For the inhibitory activity against the aggregation reaction using pectin or alginic acid, the fungal solution and the pectin or alginic acid solution were mixed and reacted at room temperature, and then the red blood cell solution was mixed and reacted, and then the aggregation reaction was measured using a microscope. . Pectin shows high inhibitory effect on hemagglutination induced by P. gingivalis , P. acnes and S. aureus , while no inhibitory effect on hemagglutination by S. epidermidis and Lactobacillus. But not to E. coli (FIG. 3).

Example  5. Hemagglutination Inhibition of Alginic Acid by Helicobacter

The cultured Helicobacter was diluted with phosphate buffer solution, mixed with the same amount of red blood cell solution, and stirred for 30 minutes to 3 hours at room temperature to react with positive red blood cell aggregation. In order to inhibit the agglutination reaction using the isolated polysaccharide fractions, the Helicobacter solution and the alginic acid solution were mixed and reacted at room temperature, and then the red blood cell solution was mixed and reacted, and then the aggregation reaction was measured using a microscope.

As a result of activity measurement that inhibits hemagglutination by Helicobacter, alginic acid showed inhibitory activity at a low concentration of 0.25 mg / ml (FIG. 4).

As described above, according to the present invention by adding the pectin inhibiting the aggregation reaction of oral disease pathogens, skin disease acne, apopy-causing bacteria and human erythrocytes, gastric disease pathogens have been invented for alginic acid. Through the present invention, oral disease, acne and atopic skin disease is expected to achieve the development effect of the leading material for preventing and treating diseases. In particular, in the case of conventional antibiotics or chemical drugs, the developmental technology as well as the side effects are cell-destructive, while new substances that inhibit carbohydrate recognition and interaction on the surface of human cells inhibit the cell-cell adhesion and binding, thereby minimizing skin diseases. In terms of destructive technology, it has the meaning of future-oriented cosmetics and medicines. In particular, in the cosmetics industry, where skin balance is important, the shift to a new concept of microbial balance in the skin expands wider marketability by using eco-friendly excellence of sugar blends to prevent or treat infections caused by bacterial invasion in the future. Is considered possible. Finally, pectin and alginic acid is a natural material, and thus is an excellent invention because it has an inhibitory effect according to the relative concentration of natural new substances.

[references]

Claims (5)

A composition for preventing and treating periodontal disease, acne, atopy or gastric disease through inhibiting human cell binding of an infectious disease pathogen containing pectin as an active ingredient. The method for preventing and treating periodontal disease, acne, atopy or gastric disease according to claim 1, wherein the infectious disease pathogen is an oral periodontal causative bacterium, a skin disease acne bacterium, an atopic skin pathogen or a stomach disease pathogen. According to claim 1, wherein the pectin is a composition for preventing and treating periodontal disease, acne, atopic or gastric disease, characterized in that the effective inhibitory activity in the concentration range of 0.0001 ~ 0.1 mg / ml. The method of claim 1, wherein the composition is a composition for preventing and treating periodontal disease, acne, atopy or gastric disease, characterized in that it has a strong specific inhibitory effect only on the hemagglutination reaction caused by infectious disease pathogens. delete

Images